Tenofovir-based PrEP for COVID-19: an untapped opportunity?

DeJong, Colette; Spinelli, Matthew A; Okochi, Hideaki; Gandhi, Monica

DeJong, Colette; Spinelli, Matthew A; Okochi, Hideaki; Gandhi, Monica.

DeJong C; Department of Medicine, University of California.
Spinelli MA; Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, USA.
Okochi H; Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, USA.
Gandhi M; Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, USA.

AIDS ; 35(9): 1509-1511, 2021 07 15.

Article in English | MEDLINE | ID: covidwho-1132676

Subject(s)

Anti-HIV Agents; COVID-19; HIV Infections; Pre-Exposure Prophylaxis; Anti-HIV Agents/therapeutic use; Emtricitabine; HIV Infections/drug therapy; Humans; Medication Adherence; SARS-CoV-2; Tenofovir

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / Pre-Exposure Prophylaxis / COVID-19 Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google